dupilumab (dupixent) Report issue

Biologics mAb Approved FDA First in Class Priority Review FDA

Active Ingredient History

NOW
  • Now
Dupilumab, sold under the brand name Dupixent, is a monoclonal antibody blocking interleukin 4 and interleukin 13, used for allergic diseases such as eczema, asthma and nasal polyps which result in chronic sinusitis. It is also used for the treatment of eosinophilic esophagitis and prurigo nodularis.   Wikipedia

More Chemistry
  • Mechanisms of Action:
  • Multi-specific: No
  • Black Box: No
  • Availability: Prescription Only
  • Delivery Methods: Parenteral
  • Pro Drug: No

Drug Pricing (per unit)

Australia

$645.0496

United States

$1079.2200 - $3321.1506
More Pricing Detail

Note: This drug pricing data is preliminary, incomplete, and may contain errors.

dupilumab | dupixent | regn668 | regn-668 | sar231893

Feedback

Data collection and curation is an ongoing process for CDEK - if you notice any information here to be missing or incorrect, please let us know! When possible, please include a source URL (we verify all data prior to inclusion).

Report issue